Clal Biotechnology Industries portfolio company MediWound announced that it has obtained positive interim results from the Phase III clinical trial of its Debrase gel dressing for the treatment of burn wounds.
MediWound is preparing an application for European Medicines Agency (EMEA) marketing approval.
The trial, that included 175 patients, showed statistically significant results for both primary targets: Reducing the need for surgical treatment for the removal of burned tissue, and reduction in the number of skin transplants. A story about the burn therapy that saves healthy tissue and reduces pain previously appeared on ISRAEL21c.
IDB Holding Corp. unit Clal Biotech owns 56 percent of MediWound and Teva Pharmaceutical Industries owns 11% and has an option to increase its stake to 25% when MediWound obtains marketing certification for Debrase.
Teva’s agreement with MediWound also covers expanding the treatment to other medical uses, marketing of Debrase in the US, and an option to develop and market the product in the US and Europe, according to a report from Israel’s leading financial daily Globes.